<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00199160</url>
  </required_header>
  <id_info>
    <org_study_id>BAY 43-9006 Head and Neck</org_study_id>
    <nct_id>NCT00199160</nct_id>
  </id_info>
  <brief_title>Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and/or Metastatic Head and Neck Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jules Bordet Institute</source>
  <brief_summary>
    <textblock>
      This is a Phase II trial evaluating the efficacy and the biological activity of BAY 43-9006&#xD;
      in patients with recurrent and/or metastatic head and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II trial evaluating the efficacy and the biological activity of BAY 43-9006&#xD;
      in patients with recurrent and/or metastatic head and neck cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
  </primary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY 43-9006</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients (18 years old and above), with a histologically proven,&#xD;
             measurable, locally recurrent, and/or metastatic head and neck tumor.&#xD;
&#xD;
          -  &gt; 4 weeks since major surgery&#xD;
&#xD;
          -  &gt; 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  &gt; 3 weeks since prior therapy with biological agents (Interleukin-2 [IL-2],&#xD;
             interferon, other molecular-targeted therapies [except Ras/Raf inhibitors]).&#xD;
&#xD;
          -  Performance status &lt; 2&#xD;
&#xD;
          -  Life expectancy &gt; 3 months.&#xD;
&#xD;
          -  At least one uni-dimensional measurable lesion by computed tomography (CT)-scan or&#xD;
             magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST)&#xD;
&#xD;
          -  Adequate liver, pancreatic, renal, and coagulation function&#xD;
&#xD;
          -  A slide or paraffin-block from a tumor biopsy MUST be available at the time of&#xD;
             screening. If the original diagnostic biopsy is not available at the time of&#xD;
             screening, an additional biopsy is required.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe preexisting conditions&#xD;
&#xD;
          -  Evidence of bone marrow suppression&#xD;
&#xD;
          -  Frequent vomiting or medical condition, which could interfere with oral medication&#xD;
             intake&#xD;
&#xD;
          -  Lack of resolution of all toxic manifestations of prior chemotherapy, biologic, or&#xD;
             radiation therapy (alopecia excluded).&#xD;
&#xD;
          -  Known HIV positivity or AIDS-related illness.&#xD;
&#xD;
          -  Previous exposure to a Ras/Raf inhibitor&#xD;
&#xD;
          -  Previous malignancy (except for cervical carcinoma in situ, adequately treated basal&#xD;
             cell carcinoma, or superficial bladder tumors [Ta, Tis and T1] or other malignancies&#xD;
             curatively treated &gt; 2 years prior to entry)&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Cardiac arrhythmias requiring anti-arrhythmics&#xD;
&#xD;
          -  Active coronary artery disease or ischaemia&#xD;
&#xD;
          -  Active clinically serious bacterial or fungal infections&#xD;
&#xD;
          -  Known brain or meningeal metastases&#xD;
&#xD;
          -  Patients with seizure disorder requiring medication (such as anti-epileptics)&#xD;
&#xD;
          -  Substance abuse, medical, psychological, or social conditions that may interfere with&#xD;
             the patient's participation in the study or evaluation of the study results&#xD;
&#xD;
          -  Known or suspected allergy to the investigational agent or any agent given in&#xD;
             association with this trial&#xD;
&#xD;
          -  Pregnant or breast-feeding patients. Women of childbearing potential must have a&#xD;
             negative pregnancy test.&#xD;
&#xD;
          -  Concurrent anti-cancer chemotherapy or immunotherapy is excluded&#xD;
&#xD;
          -  Significant surgery within four weeks prior to start of study drug&#xD;
&#xD;
          -  Investigational drug therapy outside of this trial, or any chemotherapy during or&#xD;
             within 4 weeks prior to start of study drug&#xD;
&#xD;
          -  Myelosuppressive radiotherapy within four weeks prior to start of study drug&#xD;
             (short-course non-myelosuppressive radiotherapy may be allowed based on approval of&#xD;
             principal investigators)&#xD;
&#xD;
          -  Concomitant treatment with ketoconazole, itraconazole, ritonavir, or use of grapefruit&#xD;
             juice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AHMAD AWADA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jules Bordet Institute</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>May 19, 2015</last_update_submitted>
  <last_update_submitted_qc>May 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>local recurrence and or metastatic disease</keyword>
  <keyword>Previously treated with platinum</keyword>
  <keyword>carcinoma of the head and neck</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

